Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Breast Cancer Research and Treatment|February 15, 2013
Landscape and evolution of therapeutic research for breast cancer patientsSemih Dogan, Maria Vittoria Dieci, Aicha Goubar, et al.
Breast Cancer Research : BCR|September 6, 2014
Clinical development of mTOR inhibitors in breast cancerCecile Vicier, Maria Vittoria Dieci, Monica Arnedos, et al.
Cancer Discovery|April 3, 2021
Overcoming Resistance to Tumor-Targeted and Immune-Targeted TherapiesMihaela Aldea, Fabrice Andre, Aurelien Marabelle, et al.
Nature Reviews. Clinical Oncology|July 22, 2015
Precision medicine for metastatic breast cancer--limitations and solutionsMonica Arnedos, Cecile Vicier, Sherene Loi, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancerLajos Pusztai, Kristine Broglio, Fabrice Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2012
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerFabrice Andre, Maria V Dieci, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studiesGiandomenico Roviello, Fabrice Andre, Sergio Venturini, et al.
Bulletin Du Cancer|November 12, 2003
[Exosomes and anti-tumour immunotherapy]Nathalie Chaput, Fabrice Andre, Noël E C Schartz, et al.
Briefings in Bioinformatics|January 19, 2025
A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencingArnaud Guille, José Adélaïde, Pascal Finetti, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Breast Cancer Research and Treatment|February 15, 2013
Landscape and evolution of therapeutic research for breast cancer patientsSemih Dogan, Maria Vittoria Dieci, Aicha Goubar, et al.
Breast Cancer Research : BCR|September 6, 2014
Clinical development of mTOR inhibitors in breast cancerCecile Vicier, Maria Vittoria Dieci, Monica Arnedos, et al.
Cancer Discovery|April 3, 2021
Overcoming Resistance to Tumor-Targeted and Immune-Targeted TherapiesMihaela Aldea, Fabrice Andre, Aurelien Marabelle, et al.
Nature Reviews. Clinical Oncology|July 22, 2015
Precision medicine for metastatic breast cancer--limitations and solutionsMonica Arnedos, Cecile Vicier, Sherene Loi, et al.
Lancet (London, England)|March 9, 2020
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and futureLaura M Spring, Seth A Wander, Fabrice Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancerLajos Pusztai, Kristine Broglio, Fabrice Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2012
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancerFabrice Andre, Maria V Dieci, Peter Dubsky, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studiesGiandomenico Roviello, Fabrice Andre, Sergio Venturini, et al.
Bulletin Du Cancer|November 12, 2003
[Exosomes and anti-tumour immunotherapy]Nathalie Chaput, Fabrice Andre, Noël E C Schartz, et al.
Briefings in Bioinformatics|January 19, 2025
A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencingArnaud Guille, José Adélaïde, Pascal Finetti, et al.
Pageof 15